Atossa Therapeutics
ATOS
49 hedge funds and large institutions have $14.1M invested in Atossa Therapeutics in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 18 reducing their positions, and 8 closing their positions.
1,509% more call options, than puts
Call options by funds: $1.06M | Put options by funds: $66K
0.11% less ownership
Funds ownership: 12.86% → 12.75% (-0.11%)
9% less funds holding
Funds holding: 54 → 49 (-5)
25% less capital inflows, than outflows
Capital inflows: $445K | Capital outflows: $593K
61% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 18
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$254K |
| 2 |
GSA Capital Partners
London,
United Kingdom
|
+$73.1K |
| 3 |
Squarepoint
New York
|
+$45.4K |
| 4 |
Renaissance Technologies
New York
|
+$30.1K |
| 5 |
Regions Financial Corp
Birmingham,
Alabama
|
+$21.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$138K |
| 2 |
BlackRock
New York
|
-$64.8K |
| 3 |
XTX Topco
George Town,
Cayman Islands
|
-$59K |
| 4 |
Virtu Financial
New York
|
-$59K |
| 5 |
Bank of New York Mellon
New York
|
-$42.2K |
ATOS Hedge Fund Activity: Q4 2023 in Review
49 of the 6,875 institutional investors tracked by Wall St. Rank reported a position in Atossa Therapeutics (ATOS) for Q4 2023, worth a combined $14.1M — up 18% from $11.9M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of ATOS and 3 opened new positions — a net loss of 5 holders — while 18 trimmed existing stakes and 7 added.
The largest buyer was Bank of Montreal, opening a new position worth an estimated $254K. The largest seller was Millennium Management, cutting an estimated $138K.
- 49 institutional investors held Atossa Therapeutics (ATOS) as of Q4 2023, down from 54 in Q3 2023.
- Funds reported $14.1M of Atossa Therapeutics stock for Q4 2023, up 18% quarter-over-quarter.
- 3 funds opened new Atossa Therapeutics positions in Q4 2023 and 8 closed out, a net change of -5 holders.
- The largest Atossa Therapeutics buyer in Q4 2023 was Bank of Montreal, an estimated $254K added.
- The largest Atossa Therapeutics seller in Q4 2023 was Millennium Management, an estimated $138K sold.
Based on aggregated 13F filings for Q4 2023.